FDA PUBLIC REVIEW OF OTC ANALGESIC INDICATIONS
This article was originally published in The Tan Sheet
Executive Summary
FDA PUBLIC REVIEW OF OTC ANALGESIC INDICATIONS will take place "hopefully...this year," Office of OTC Drug Evaluation Director Michael Weintraub, MD, told the Senate Appropriations/agriculture subcommittee at a May 10 hearing on FDA's fiscal 1995 budget. In response to a series of questions regarding FDA's Rx-to-OTC switch review process from Sen. Thad Cochran (R-Miss.), Weintraub said the OTC office has "set up hopefully for later this year a larger open committee meeting with all sorts of experts in the field of pain and...what we call analgesiology."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning